Nanomachines loaded with wine ingredients overcome gene therapy challenges
Researchers have demonstrated, for the first time in the world using mice, the ability to overcome significant challenges in ...
GEN6d
Optimizing AAV Gene Delivery: Hitting the Target Safely and Effectively
Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.
GEN10d
Purification Option Eases the Bottlenecks in AAV Production
A new, streamlined AAV purification process that is both universal and scalable could ease commercialization constraint.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic ...
Contract Pharma3d
Affinia Names Chief Medical Officer
Affinia Therapeutics, a gene therapy company with a pipeline of adeno-associated virus (AAV) gene therapies for devastating ...
Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene Therapy Candidate for Gaucher Disease
FDA aligned on single-arm Phase 3 study to support potential accelerated and full approvalOn track to dose first patient in Phase 3 trial in ...
News Medical on MSN5d
USC receives $6 million grant for pioneering glioblastoma gene therapy
The California Institute for Regenerative Medicine has awarded a $6 million grant to USC investigators pioneering a new first ...
American Association of Individual Investors2d
Why Neurogene Inc.’s (NGNE) Stock Is Down 12.19%
Neurogene Inc.’s NGNE share price has dipped by 12.19%, which has investors questioning if this is right time to buy.